Publications: IBS (23)

Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome - PubMed (nih.gov). Aliment Pharmacol Ther. 2022 Sep 29. doi: 10.1111/apt.17239. Epub ahead of print. PMID: 36173041.

El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation - PubMed (nih.gov) Gastroenterology. 2022 Jun 13:S0016-5085(22)00625-4. doi: 10.1053/j.gastro.2022.06.020. Epub ahead of print. PMID: 35709830.

Iribarren C, Nordlander S, Sundin J, Isaksson S, Savolainen O, Törnblom H, Magnusson MK, Simrén M, Öhman LFecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids - PubMed (nih.gov). Neurogastroenterol Motil. 2022 Apr 29:e14390. doi: 10.1111/nmo.14390. Epub ahead of print. PMID: 35485994.

El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. The fecal microbiota transplantation response differs between patients with severe and moderate irritable bowel symptoms - PubMed (nih.gov). Scand J Gastroenterol. 2022 Apr 29:1-10. doi: 10.1080/00365521.2022.2064725. Epub ahead of print. PMID: 35486073.

El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG. Irritable bowel syndrome patients who are not likely to respond to fecal microbiota transplantation - PubMed (nih.gov). Neurogastroenterol Motil. 2022 Mar 18:e14353. doi: 10.1111/nmo.14353. Epub ahead of print. PMID: 35302268.

Rej A, Sanders DS, Shaw CC, Buckle R, Trott N, Agrawal A, Aziz I. Efficacy and Acceptability of Dietary Therapies in Non-Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten-Free Diet - PubMed (nih.gov). Clin Gastroenterol Hepatol. 2022 Feb 28:S1542-3565(22)00202-6. doi: 10.1016/j.cgh.2022.02.045. Epub ahead of print. PMID: 35240330.

Colomier E, Van Oudenhove L, Tack J, Böhn L, Bennet S, Nybacka S, Störsrud S, Öhman L, Törnblom H, Simrén M. Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome - PubMed (nih.gov). Nutrients. 2022 Jan 17;14(2):397. doi: 10.3390/nu14020397. PMID: 35057578; PMCID: PMC8780869.

Vasapolli R, Schulz C, Schweden M, Casèn C, Kirubakaran GT, Kirste KH, Macke L, Link A, Schütte K, Malfertheiner P. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID) - PubMed (nih.gov). Eur J Clin Invest. 2021 Aug 14:e13666. doi: 10.1111/eci.13666. Epub ahead of print. PMID: 34390492.

El-Salhy M, Kristoffersen AB, Valeur J, Casen C, Hatlebakk JG, Gilja OH, Hausken T. Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome - PubMed (nih.gov). Neurogastroenterol Motil. 2021 Jun 18:e14200. doi: 10.1111/nmo.14200. Epub ahead of print. PMID: 34145677.

Ahluwalia B, Iribarren C, Magnusson MK, Sundin J, Clevers E, Savolainen O, Ross AB, Törnblom H, Simrén M, Öhman LA Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome - PubMed (nih.gov). Cells. 2021 Jun 10;10(6):1459. doi: 10.3390/cells10061459. PMID: 34200772; PMCID: PMC8230381.

El-Salhy M, Casen C, Valeur J, Hausken T, Hatlebakk JG. Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome - PubMed (nih.gov). World J Gastroenterol 2021; 27(18): 2219-2237 [DOI: 10.3748/wjg.v27.i18.2219]

Mazzawi T, El-Salhy M, Lied GA, Hausken T. The Effects of Fecal Microbiota Transplantation on the Symptoms and the Duodenal Neurogenin 3, Musashi 1, and Enteroendocrine Cells in Patients With Diarrhea-Predominant Irritable Bowel Syndrome - PubMed (nih.gov). Front Cell Infect Microbiol. 2021 May 12;11:524851. doi: 10.3389/fcimb.2021.524851. PMID: 34055657; PMCID: PMC8149964.

Berentsen B, Nagaraja BH, Teige EP, Lied GA, Lundervold AJ, Lundervold K, Steinsvik EK, Hillestad ER, Valeur J, Brønstad I, Gilja OH, Osnes B, Hatlebakk JG, Haász J, Labus J, Gupta A, Mayer EA, Benitez-Páez A, Sanz Y, Lundervold A, Hausken T. Study protocol of the Bergen brain-gut-microbiota-axis study: A prospective case-report characterization and dietary intervention study to evaluate the effects of microbiota alterations on cognition and anatomical and functional brain connectivity in patients with irritable bowel syndrome - PubMed (nih.gov). Medicine (Baltimore). 2020 Sep 11;99(37):e21950. doi: 10.1097/MD.0000000000021950. PMID: 32925728; PMCID: PMC7489588.

Iribarren C, Törnblom H, Aziz I, et al. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study - PubMed (nih.gov) [published online ahead of print, 2020 Jun 14]. Neurogastroenterol Motil. 2020;e13920.

Mazzawi T, Eikrem Ø, Lied GA, Hausken T. Abnormal Uroguanylin Immunoreactive Cells Density in the Duodenum of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Changes following Fecal Microbiota Transplantation - PubMed (nih.gov). Gastroenterol Res Pract. 2020;2020:3520686. Published 2020 Feb 4.

El-Salhy M, Hatlebakk JG, Gilja OH, Bråthen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study - PubMed (nih.gov). Gut. 2020;69(5):859-867.

El-Salhy M, Hausken T, Hatlebakk JGIncreasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS) - PubMed (nih.gov). Nutrients. 2019;11(6):1415. Published 2019 Jun 24.

Mazzawi T, Lied GA, Sangnes DA, et al The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation - PubMed (nih.gov). PLoS One. 2018;13(11):e0194904. Published 2018 Nov 14.

Bennet SMP, Böhn L, Störsrud S, et al. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs - PubMed (nih.gov). Gut. 2018;67(5):872-881.

Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome - PubMed (nih.gov). Dig Dis Sci. 2018;63(2):429-436.

Aasbrenn M, Valeur J, Farup PG. Evaluation of a faecal dysbiosis test for irritable bowel syndrome in subjects with and without obesity - PubMed (nih.gov). Scand J Clin Lab Invest. 2018;78(1-2):109-113.

Hustoft TN, Hausken T, Ystad SO, et al. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome - PubMed (nih.gov). Neurogastroenterol Motil. 2017;29(4):10.1111/nmo.12969.

Casén C, Vebø HC, Sekelja M, et al. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD - PubMed (nih.gov). Aliment Pharmacol Ther. 2015;42(1):71-83.